BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19188815)

  • 1. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.
    Phillips V; Kelly P; McCluggage WG
    Int J Gynecol Pathol; 2009 Mar; 28(2):179-86. PubMed ID: 19188815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
    O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
    Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.
    Acs G; Pasha T; Zhang PJ
    Int J Gynecol Pathol; 2004 Apr; 23(2):110-8. PubMed ID: 15084838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.
    Assem H; Rambau PF; Lee S; Ogilvie T; Sienko A; Kelemen LE; Köbel M
    Am J Surg Pathol; 2018 Apr; 42(4):534-544. PubMed ID: 29309296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
    Al-Hussaini M; Stockman A; Foster H; McCluggage WG
    Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of WT1, B-cell lymphoma 2, Ki-67 (Mib1), and Her2/Neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma.
    Mondal SK; Basak B; Bhattacharya S; Panda UK
    J Cancer Res Ther; 2021; 17(1):164-169. PubMed ID: 33723149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The study of p53 and p16 immunoexpression in serous borderline and malignant ovarian tumors.
    Marinaş MC; Mogoş DG; Simionescu CE; Stepan A; Tănase F
    Rom J Morphol Embryol; 2012; 53(4):1021-5. PubMed ID: 23303027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
    Boyd C; McCluggage WG
    Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
    Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
    APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
    Rambau PF; Vierkant RA; Intermaggio MP; Kelemen LE; Goodman MT; Herpel E; Pharoah PD; Kommoss S; Jimenez-Linan M; Karlan BY; Gentry-Maharaj A; Menon U; Polo SH; Candido Dos Reis FJ; Doherty JA; Gayther SA; Sharma R; Larson MC; Harnett PR; Hatfield E; de Andrade JM; Nelson GS; Steed H; Schildkraut JM; Carney ME; Høgdall E; Whittemore AS; Widschwendter M; Kennedy CJ; Wang F; Wang Q; Wang C; Armasu SM; Daley F; Coulson P; Jones ME; Anglesio MS; Chow C; de Fazio A; García-Closas M; Brucker SY; Cybulski C; Harris HR; Hartkopf AD; Huzarski T; Jensen A; Lubiński J; Oszurek O; Benitez J; Mina F; Staebler A; Taran FA; Pasternak J; Talhouk A; Rossing MA; Hendley J; ; Edwards RP; Fereday S; Modugno F; Ness RB; Sieh W; El-Bahrawy MA; Winham SJ; Lester J; Kjaer SK; Gronwald J; Sinn P; Fasching PA; Chang-Claude J; Moysich KB; Bowtell DD; Hernandez BY; Luk H; Behrens S; Shah M; Jung A; Ghatage P; Alsop J; Alsop K; García-Donas J; Thompson PJ; Swerdlow AJ; Karpinskyj C; Cazorla-Jiménez A; García MJ; Deen S; Wilkens LR; Palacios J; Berchuck A; Koziak JM; Brenton JD; Cook LS; Goode EL; Huntsman DG; Ramus SJ; Köbel M
    J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Santón A; Gonzalez BO; López-Reig R; Hardisson D; Vera-Sempere F; Illueca C; Vieites B; López-Guerrero JA; Palacios J; Poveda A
    Am J Surg Pathol; 2020 Feb; 44(2):149-161. PubMed ID: 31498173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.